NCT05085626 is a Phase 2 clinical trial of fluzoparib+chidamide in Advanced HER2 Negative Breast Carcinoma, sponsored by Tianjin Medical University Cancer Institute and Hospital.

Who is sponsoring NCT05085626?

NCT05085626 is sponsored by Tianjin Medical University Cancer Institute and Hospital.

What drugs are being tested in NCT05085626?

Interventions in NCT05085626: fluzoparib+chidamide, fluzoparib+camrelizumab.

What condition does NCT05085626 study?

NCT05085626 studies Advanced HER2 Negative Breast Carcinoma, HRD+Breast Cancer.

Is NCT05085626 still recruiting?

NCT05085626 is currently status unknown. Last updated 29 September 2022.

Last reviewed 2022-09-29 · How we verify

NCT05085626

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer

Status unknown Phase 2 Last updated 29 September 2022

What this trial tests

Phase 2 trial testing fluzoparib+chidamide in Advanced HER2 Negative Breast Carcinoma in 40 participants. Status unknown.

Timeline

8 February 2021

Primary endpoint
31 October 2023

31 December 2024

Quick facts

Lead sponsor	Tianjin Medical University Cancer Institute and Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	8 February 2021
Primary completion	31 October 2023
Estimated completion	31 December 2024
Sites	1 location across China

Drugs / interventions tested

fluzoparib+chidamide — full drug profile →
fluzoparib+camrelizumab — full drug profile →

Conditions studied

Advanced HER2 Negative Breast Carcinoma — all drugs for Advanced HER2 Negative Breast Carcinoma →
HRD+Breast Cancer — all drugs for HRD+Breast Cancer →

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Who can join

Adults 18 to 70, female only, with Advanced HER2 Negative Breast Carcinoma or HRD+Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is planned to include 40 patients with HER2-negative advanced breast cancer to receive fluzoparib combined with chidamide or fluzoparib combined with camrelizumab to observe and evaluate the efficacy and safety of fluzoparib combined with camrelizumab or chidamide in the treatment of HRD-positive HER2-negative advanced breast cancer.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Emerging Role of Epigenetic Modifiers in Breast Cancer Pathogenesis and Therapeutic Response.
Lee RS, Sad K, Fawwal DV, Spangle JM. · · 2023 · cited 17× · PMID 37568822 · DOI 10.3390/cancers15154005
Pan-cancer analysis of homologous recombination deficiency and homologous recombination repair-associated gene alterations in solid tumors from a large Asian cohort.
Ren L, Yao R, Hou T, Liu C, et al · · 2025 · cited 5× · PMID 40420266 · DOI 10.1186/s12885-025-14267-w
Histone acetylation modulators in breast cancer.
Yuan X, Rosen JM. · · 2025 · cited 4× · PMID 40165290 · DOI 10.1186/s13058-025-02006-9
Immunotherapy and its racial specificity for breast cancer treatment in Asia: a narrative review.
Xu RC, Zhang YW, Liu CC, Xu YY, et al · · 2025 · cited 3× · PMID 40443538 · DOI 10.1016/j.lanwpc.2024.101180
The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancers.
Xu Q, Wen Y, Huang T, Li H, et al · · 2025 · cited 1× · PMID 40830526 · DOI 10.1186/s40364-025-00814-x

Verify or expand the search:

Other Tianjin Medical University Cancer Institute and Hospital trials

Trials by the same sponsor.

NCT07493993 — Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoa · Phase 2 · not yet recruiting
NCT07515469 — A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD · Phase 2 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07510594 — A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC · Phase 2 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05085626 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Cancer Institute and Hospital
Last refreshed: 29 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05085626.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing